---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000030"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:22:08.354837+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ligand Q1 royalty revenue +56% to $43M; reaffirms raised guidance amid XOMA acquisition

## Summary
- Q1 royalty revenue $43.0M (+56% YoY); total revenue $51.7M (+14%).
- GAAP net loss $13.3M ($0.67/sh) vs loss $42.5M ($2.21/sh) prior yr; adj EPS $1.63 (+23%).
- Reaffirms FY2026 guidance: royalty rev $225-250M, total rev $270-310M, adj EPS $8.50-9.50.
- Acquiring XOMA for $39/share in cash + CVR; adds over 120 assets incl. Vabysmo, Ojemda, Miplyffa.
- Cash and investments $779.4M at Mar 31; deal expected to close Q3 2026.

## SEC filing metadata
- accession: 0000886163-26-000030
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/0000886163-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/lgnd-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000030
- JSON: https://secwatch.observer/filing/0000886163-26-000030.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000030.txt

## Source-grounded claims
- claim_id: d727f3b15baffb6da74176d40132edcaa3502e53
  claim: LIGAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $51.7 million, net income GAAP net loss was $13.3 million, or $0.67 per share, EPS $0.67 per share. Guidance reaffirmed.
  evidence_excerpt: results reflect continued strong momentum in the royalty business, with royalty revenue growing 56% year-over-year. Total revenues and income for the first quarter of 2026 were $51.7 million, compared with $45.3 million for the same period in 2025, with the 14% increase primarily driven by higher royalty revenue. Royalties for the first quarter of 2026 were $43.0
  evidence_url: https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/0000886163-26-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.